• 1
    Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353(9160):12581265.
  • 2
    Andersen BS, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium—an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998;77(2):170173.
  • 3
    Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium: I. Normal condition. Gynecol Obstet Invest 1981;12(3):141154.
  • 4
    Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984;52(2):176182.
  • 5
    Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173(1):210213.
  • 6
    Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68(1):122140.
  • 7
    Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119(1 Suppl):122S131S.
  • 8
    Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337(10):688698.
  • 9
    Greer IA. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology. Baillieres Clin Obstet Gynaecol 1997;11(3):403430.
  • 10
    Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81(5):668672.
  • 11
    Sorensen HT, Johnsen SP, Larsen H, Pedersen L, Nielsen GL, Moller M. Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet Gynecol Scand 2000;79(8):655659.
  • 12
    Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001;108(11):11341140.
  • 13
    Laifer SA, Stiller RJ, Dunston-Boone G, Whetham JC. Low-molecular weight heparin for treatment of pulmonary embolism in a pregnant woman. Thromb Haemost 1999;82(4):13611362.
  • 14
    Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb Res 1984;34(6):557560.
  • 15
    Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 1987;57(2):234.
  • 16
    Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism—results from a randomized, double-blind, clinical trial. Thromb Haemost 2001;85(5):775781.
  • 17
    Thomson AJ, Walker ID, Greer IA. Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy. Lancet 1998;352(9144):1904.
  • 18
    Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997;77(1):3943.
  • 19
    Crowther MA, Spitzer K, Julian J, et al. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study. Thromb Res 2000;98(2):133138.
  • 20
    Bremme K, van Rooijen M, Yu A, Blomback M. Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy. Blood Coagul Fibrinolysis 2001;12(2):149155.
  • 21
    Roberts N, Ross D, Flint SK, Arya R, Blott M. Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. Br J Obstet Gynaecol 2001;108(3):327329.
  • 22
    Ellison J, Thomson AJ, Walker ID, Greer IA. Use of enoxaparin in a pregnant woman with a mechanical heart valve prosthesis. Br J Obstet Gynaecol 2001;108(7):757759.
  • 23
    Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71(1):711.
  • 24
    Gerhardt A, Zotz RB, Struve S, Scharf RE. Homozygous and combined heterozygous factor V G1619A and prothrombin G20210A mutations are predictors of venous thrombosis during pregnancy [abstract 2982]. Thromb Haemost. 2001;Suppl (CD).